The firm recently had a successful end-of-Phase II meeting with the FDA, in which the agency provided feedback into a Phase III trial design.

In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.

The firm will use the funds to advance its mRNA therapies, including its lead candidate STX-001 for treating melanoma and triple-negative breast cancer.

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

Researchers at Stanford and St. Jude aim to bring PGx resources under one new umbrella and accelerate the discipline's ...

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Patients must express PPARG in at least 60 percent of tumor cells to enroll in the trial and receive the investigational drug.

The operating efficiency effort includes "employment-related and other operating expense reductions in early research," the firm said.

NEW YORK – A first-in-human Phase I trial is underway testing Atavistik Bio's ATV-1601 in patients with AKT1 E17K-mutated solid tumors, the Cambridge, Massachusetts-based company announced this week.

NEW YORK – Xoma Royalty on Monday said it will acquire Lava Therapeutics and discontinue developing its lead leukemia treatment candidate LAVA-1266, a CD123-targeted bispecific gamma delta T-cell ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

BioCardia wants to gauge whether it has enough evidence to pursue regulatory approval for CardiAMP in ischemic heart failure.